2024-09-30 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report 

**1. Performance Comparison and Divergence**

* **Company:** AbbVie Inc. is a leading pharmaceutical company specializing in the development and commercialization of innovative treatments for various diseases.
* **Cumulative Returns:** ABBV has achieved a cumulative return of 154.25%, outperforming the S&P 500 (VOO) which has returned 133.28%.
* **Divergence:** ABBV is currently outperforming the S&P 500 by 20.97%, which represents a relative divergence of 62.07% based on historical data. This suggests that ABBV has outperformed the market by a significant margin in recent periods.

**2. Recent Price Movements**

* **Closing Price:** $195.07
* **Moving Averages:**
    * 5-day: $193.31
    * 20-day: $194.53
    * 60-day: $187.45

The stock is trading above all three moving averages, indicating positive momentum and potential for further upside.

**3. Technical Indicators**

* **RSI (Relative Strength Index):** 46.88. The RSI suggests that ABBV is trading in a neutral territory, neither overbought nor oversold.
* **PPO (Percentage Price Oscillator):** -0.28. The negative PPO value indicates a potential for a short-term price correction.
* **Delta_Previous_Relative_Divergence:** -5.27. The negative value suggests a short-term downward trend in relative divergence.
* **Expected Return:** 4.74%. This represents a potential 5-year estimated return based on current investment levels.

**4. Recent Earnings and Outlook**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

ABBV has consistently exceeded earnings expectations in recent quarters, indicating strong financial performance and a positive outlook. The most recent earnings release on July 25th showed an EPS of 2.65, exceeding the expected EPS of 2.57. This further solidifies the company's strong performance and reinforces investor confidence.

**5. News and Recent Issues**

* **Recent Market Outlook:** According to FINBOLD, ABBV is expected to benefit from the growing demand for its key products, particularly Humira, a blockbuster biologic treatment for various autoimmune diseases. The company is also investing heavily in R&D to diversify its portfolio and maintain a competitive edge in the pharmaceutical market. 
* **Analyst Opinions:** Most analysts maintain a positive outlook on ABBV, citing its strong market position, robust pipeline, and attractive dividend yield.
* **Performance Highlights:** ABBV's recent performance has been driven by several factors, including the continued success of Humira, the introduction of new drugs like Rinvoq and Skyrizi, and strategic acquisitions.

**6. Overall Analysis**

ABBV presents a compelling investment opportunity with a strong track record of outperformance, solid fundamentals, and positive growth prospects. The company's earnings performance, robust pipeline, and favorable market dynamics suggest potential for continued growth and value creation for investors. However, the recent short-term downward trend in relative divergence and negative PPO value suggest a potential for a short-term price correction. 

**7. Recommendations**

Based on the analysis, ABBV appears to be a promising investment opportunity for long-term investors seeking exposure to the pharmaceutical sector. However, given the potential for short-term volatility, investors may consider adopting a cautious approach and monitoring the stock closely for any potential price adjustments.  
